Draftkings Inc. diskutieren
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $44.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $44.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $37.00 price target on the stock, up previously from $26.00.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $37.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $44.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Guggenheim from $38.00 to $37.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Morgan Stanley from $35.00 to $36.00. They now have an "overweight" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $44.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) was upgraded by analysts at Moffett Nathanson from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Susquehanna from $40.00 to $37.00. They now have a "positive" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Needham & Company LLC from $44.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Truist Financial Co. from $44.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at UBS Group AG from $39.00 to $44.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Susquehanna from $37.00 to $42.00. They now have a "positive" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Benchmark Co. from $37.00 to $41.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Guggenheim from $39.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Craig Hallum from $40.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
Neueste Beiträge
StockNews_com in Ampio Pharmaceuticals Inc. diskutieren